McMaster researchers identify biological pathway behind statin-related muscle pain
By
Circe Luna Cordeiro
Summary
McMaster University researchers have identified a biological pathway that may explain why some people experience muscle pain, weakness, and exercise intolerance when taking statins, a widely used cholesterol-lowering medication. This discovery could lead to new treatments that preserve the cardiovascular benefits of statins while reducing their musculoskeletal side effects, potentially helping millions of patients who struggle with or discontinue statin therapy due to muscle problems.
Source
Twitter / XMcMaster researchers identify biological pathway behind statin-related muscle painhealthsci.mcmaster.caKey quotes
· 3 pulledMillions of people rely on statins – a medication used to lower cholesterol and reduce the risk of heart attack and stroke.
But for some, the drugs come with an unwelcome trade-off: muscle pain, weakness and exercise intolerance that can make it difficult to continue treatment.
Now, researchers at McMaster University have uncovered a biological pathway that may explain why those side effects occur.
You might also wanna read
Achy Muscles from Statins? 4 Possible Solutions to Discuss with Your Doctor
New calculator reveals whether you should really worry about statin side effects
Revolutionizing Aging: Researchers Pioneer Magnetic Therapy to Combat Physical Declines
Microvascular hypoxia and inflammation as unified drivers of chronic pain syndromes
This opinion article proposes that compromised microvascular perfusion (capillary constriction, hypoxia) and inflammation are fundamental, i
Mitochondria-derived vesicles with bioenergetic units from brown adipose tissue attenuate cardiac remodeling post-myocardial infarction
Cardiovascular Disease Prevention Through Pharmaceutical LDL Reduction
The article argues that cardiovascular disease (CVD) is effectively a solved problem due to modern pharmaceutical interventions. It explains
totalhealthoptimization.com·6mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.